9 stories mentioning GSK.L
Every FINWIRES story that references GSK.L, newest first.
Intron Health on Wednesday upgraded British pharmaceutical company GSK (GSK.L) to hold from sell and raised its price target to 20 pounds sterling from 19 pounds.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
London's FTSE 100 dropped 1.41% on Tuesday's close as oil prices trended down with Iran and Israel's renewed efforts towards restoring peace.US President Donald Trump told reporters that Washington was "very close to having a good strong powerful deal" and that they "could have an idea on Iran in one or two days now," Deutsche Bank Research noted. Israel and Iran agreed to halt direct military strikes on each other the night before.In corporate news, drugmaker GSK (GSK.L) fell 0.50% after agreeing to acquire US-based oncology-focused biopharmaceutical company Nuvalent for $10.6 billion. "The acquisition provides GSK with immediate new sales growth opportunities, improving profit contributions from 2027, and a platform in lung cancer for rapid expansion with Ris-Rez, our B7-H3 targeted ADC in phase III clinical development," GSK Chief Executive Luke Miels said.Information analytics group Relx (REL.L) launched a share buyback program of up to 200 million pounds sterling. The new program will run until June 26, and shares acquired under the scheme will be held in treasury. The stock was flat at close.On the economic front, the UK's retail sales rose 3.4% year over year on a like-for-like basis in May, following a 3.4% decline in April, according to data from the British Retail Consortium. The reading, which surpassed the expected 0.6% increase for the month, marks the strongest retail sales growth since April 2025 due to demand for outdoor and summer goods amid a heatwave."While the sunshine gave retail a welcome lift, this momentum should not be taken for granted. Household finances remain under pressure, consumer confidence is still fragile, and many retailers continue to face rising costs. If Government wants to keep inflation in check and support growth, it must urgently tackle the taxes and levies that are driving up energy bills. Without action, cost pressures will build further, limiting retailers' ability to invest and pushing prices up for customers," BRC Chief Executive Helen Dickinson said.Meanwhile, the UK launched a long-term artificial intelligence hardware strategy aimed at supporting domestic chipmakers and expanding national computing infrastructure. A 400 million-pound-sterling fund will support the initiative, as the UK seeks to equip its next national AI supercomputer with next-generation chips, UK Chancellor Rachel Reeves said at an AI Adoption Summit. Reeves also confirmed that the British government plans to launch a formal tender process for the new national supercomputer in Edinburgh.
UK pharmaceutical giant GSK (GSK.L) said Tuesday it agreed to acquire Nasdaq-listed oncology-focused biopharmaceutical company Nuvalent for $10.6 billion.Under the deal, GSK will launch a tender offer to acquire Nuvalent's entire share capital at $124 per share in cash. GSK will fund the transaction primarily from new and existing debt facilities plush cash, with its aggregate investment estimated at $9.4 billion.The planned acquisition gives GSK access to three lung cancer therapies: zidesamtinib, neladalkib and NVL-330. Both zidesamtinib and neladalkib are in late-stage studies for the treatment of non-small cell lung cancer, or NSCLC, and have received breakthrough therapy and orphan drug designations from the US Food and Drug Administration.On the other hand, NVL-330, a potential HER2 inhibitor, is in phase I trials for HER2-altered NSCLC. The deal also covers Nuvalent's preclinical portfolio of multiple programs.GSK Chief Executive Officer Luke Miels said the acquisition is "consistent with our approach to acquire assets that have clinically proven targets and meaningfully address an efficacy and/or tolerability gap."Management expects the acquisition to contribute toward revenue growth from 2027 and to be incremental in achieving its sales goal of more than 40 billion pounds sterling by 2031.With an expected deal closing in the third quarter, GSK anticipates low single-digit percentage dilution to core EPS for 2026, 2027 and 2028. However, it maintained its 2026 full-year guidance range of 7% to 9% growth in core operating profit and core EPS.GSK shares were down 3% in early morning trading in London.
London's FTSE 100 closed 1.26% higher on Monday as the International Monetary Fund increased its 2026 growth forecast for the UK to 1% from 0.8%, while investors also monitored political developments surrounding Prime Minister Keir Starmer."In the UK, Labour's decision to let [Mayor of Greater Manchester] Andy Burnham seek a return to parliament sharpens the leadership crisis facing Prime Minister Keir Starmer after heavy local election losses, which have already prompted intensified calls for him to resign," Danske Bank said."The risk is that a new, further left, prime minister pursues policies that further add to business costs, eroding profit margins and putting upward pressure on inflation," according to Berenberg. "Were a new prime minister to water down or abandon fiscal tightening at the same time, the [Bank of England] would have to set higher interest rates to prevent excess demand and inflation. The resulting combination of higher interest rates and lower profits would result in an inadequate rate of return for companies to invest and hurt the UK's long-term growth prospects."Meanwhile, the UK government and the Gulf Cooperation Council are reportedly nearing a free trade agreement after years of talks, according to London's Financial Times. In an emailed statement to, a UK government spokesperson said negotiations are continuing and remain a priority for the government.In corporate news, mining major Anglo American (AAL.L) dropped 1.36% after agreeing to sell its Australian steelmaking coal mines to Dhilmar for up to $3.88 billion in cash.Pharmaceutical giant GSK (GSK.L) gained 0.75% as Japan's health regulator expanded the eligible age range for its respiratory syncytial virus vaccine, Arexvy, to include at-risk patients aged 18 to 49.Investors will also look ahead this week to UK unemployment data for March on Tuesday, April inflation figures on Wednesday, S&P Global PMI data for May on Thursday, and retail sales numbers on Friday.
Morningstar on Wednesday upgraded British drugmaker GSK (GSK.L) to buy from hold, while keeping its price target at 22 pounds sterling.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
GSK (GSK.L) agreed to an exclusive strategic collaboration with Hong Kong-listed Sino Biopharmaceutical that will see the British pharmaceutical giant's potential treatment for chronic hepatitis B get scaled access to over 5,000 medical centers in mainland China at launch.Bepirovirsen was accepted for priority regulatory review in China in April on the back of positive results from the B-Well 1 and B-Well 2 phase 3 trials, according to a Monday release. The trials showcased statistically significant and clinically meaningful functional cure rates for hepatitis B, which can cause both acute and chronic liver disease.Under the initial 5.5-year deal, Sino Biopharmaceutical unit Chia Tai Tianqing Pharmaceutical Group will purchase the drug from GSK and handle its import, distribution, hospital access, and commercialization in mainland China. The term may be extended, subject to mutual agreement.Meanwhile, GSK will retain marketing authorization and remain responsible for regulatory, quality, pharmacovigilance, and global strategy matters. The global biopharma company will also be able to review certain early-stage pipeline assets of Sino Biopharmaceutical to evaluate the potential for collaboration opportunities outside China.Besides its priority review and breakthrough therapy designation in China, bepirovirsen has received priority review, fast track and breakthrough labels from the US Food and Drug Administration, and SENKU designation in Japan for an expedited assessment.
British shares retreated on Wednesday, with the FTSE 100 closing 1.16% lower, as investors weighed corporate earnings and geopolitical developments, including reports of US preparations for a prolonged naval blockade in the Strait of Hormuz.GSK (GSK.L), down 5.42%, was the second-worst performer on the blue-chip index. The drugmaker confirmed its 2026 growth guidance and logged a rise in first-quarter attributable profit to 1.74 billion pounds sterling from 1.62 billion pounds a year ago, in line with the FactSet-compiled consensus estimate."GSK has made a strong start to 2026, with good performance from our key growth drivers. Alongside operational delivery, we are focused on execution and accelerating R&D," Chief Executive Officer Luke Miels said.Haleon (HLN.L) also upheld its 2026 growth outlook while first-quarter revenue inched up year over year to 2.86 billion pounds from 2.85 billion pounds amid a weak cold and flu season. The consumer healthcare company's shares were down 3.08% in the closing trade."Q1 top-line growth performance came in line with expectations, albeit a volume decline was softer-than-expected (versus Visible Alpha consensus). Consistent with Reckitt, a weak cold & flu season affected its performance across regions while consumption in Europe remained soft and growth in [Latin America] slowed," RBC Capital Markets said.Meanwhile, energy distributor DCC (DCC.L) confirmed it received indicative cash proposals from a consortium comprising US investment companies Energy Capital Partners and KKR, sending its shares 9.29% higher. The consortium has until June 10 to make a firm offer for the group.On the regulatory front, British communications services watchdog Ofcom launched an inquiry into BT Group (BT-A.L) for potentially failing to comply with its requirements tied to information requests issued to its entities. The regulator said the move does not imply any findings at this stage and that it will review the available evidence before deciding whether enforcement action is warranted. The company's shares lost 1.16% at close.
British equities closed in the red on Monday, with the FTSE 100 down 0.56%, as investors remained cautious ahead of upcoming corporate earnings and key central bank rate decisions, including from the Bank of England."Even if recent data has come in quite solid, the UK labour market is much cooler and the starting point for the Bank Rate at 3.75% is much higher compared to 2022. Hiking rates will have to be weighed against a considerable risk of exacerbating a looming economic contraction. We think it is most likely the BoE will remain sidelined for the foreseeable future," Danske Bank said.Meanwhile, the Confederation of British Industry distributive trades survey's retail sales balance fell to -68% in April from -52% in March. The consensus estimate was -42% for the month, according to Investing.com."With the economic impact of the Iran conflict becoming clearer, firms will be looking to government to recognise that easing cost of living pressures depends on tackling the cost of doing business. For the distribution sector, that means securing appropriate landing zones on the Employment Rights Act, delivering meaningful business rates reform, and exploring further how non-energy policy costs can be removed from electricity bills," CBI lead economist Martin Sartorius said.In corporate news, GSK (GSK.L), down 0.20%, had a busy start to the new week. Aside from completing a license agreement for its cholestatic pruritus treatment, linerixibat, with Alfasigma, the British pharmaceutical giant also secured breakthrough therapy and priority medicines designations in the US and Europe, respectively, for its once-monthly investigational liver therapy, efimosfermin.Meanwhile, the Delaware Chancery Court in the US granted the motion to dismiss filed by AnaptysBio against GSK subsidiary Tesaro, with the latter affirming its view that the anticipatory breach claim is entirely without merit.
GSK (GSK.L) received approval from China's National Medical Products Administration for Blenrep, providing a new treatment option for patients with relapsed or refractory multiple myeloma amid the continued rise in cases in the country.In a Monday filing, the biopharma company noted that China's multiple myeloma cases have doubled to 30,000 annually, with mortality rising 50% over three decades. Globally, the "treatable but incurable" disease is considered the third most common blood cancer, with 180,000 new cases diagnosed yearly.Following a priority review by the Chinese regulator, the monoclonal antibody-drug conjugate was cleared for use in combination with bortezomib and dexamethasone to treat adult patients who have undergone at least one prior line of therapy.The approval was backed by data from the Dreamm-7 phase 3 study, with the Blenrep regimen delivering "statistically significant and clinically meaningful" progression-free survival and overall survival results against the daratumumab-based triplet combination with bortezomib and dexamethasone. Additionally, the Blenrep combination maintained a consistent safety profile with the documented safety characteristics of the individual medications involved."Today's approval of Blenrep brings anti-[B-cell maturation antigen] therapy to patients in China with relapsed or refractory multiple myeloma in 2L+, introducing a differentiated mechanism of action with the potential to help slow disease progression and extend survival. Further, Blenrep, as the only anti-BCMA ADC, is fully outpatient administered, so patients can be treated at any site of care without complex pre-administration regimens or hospitalisation," said Hesham Abdullah, senior vice president, global head oncology, research & development at GSK.With more than 15 authorizations internationally, Blenrep is an established treatment for second-line plus multiple myeloma across markets, including the European Union, the UK, and Japan. The approved combinations include dexamethasone and either bortezomib or pomalidomide.GSK's London-listed stock was marginally down by Monday midday trade.